UPDATE: William Blair Starts Ginkgo Bioworks Holdings Inc (DNA) at Outperform

William Blair analyst Matt Larew initiates coverage on Ginkgo Bioworks Holdings Inc (NYSE: DNA) with a Outperform rating.

The analyst comments "We expect Ginkgo to capture considerable value by democratizing cell programming. Ginkgo’s platform enables companies to harness the power of synthetic biology without having to vertically integrate for product development, and the company is attempting to create a low-code platform compared with the more manual coding effort required to pursue synthetic biology projects historically. As a result, we believe Ginkgo will be able to democratize cell programming, ultimately allowing the company to capture a portion of the total addressable market of the entire synthetic biology sector."

For an analyst ratings summary and ratings history on Ginkgo Bioworks Holdings Inc click here. For more ratings news on Ginkgo Bioworks Holdings Inc click here.

Shares of Ginkgo Bioworks Holdings Inc closed at $9.47 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Goldman Sachs Upgrades Plains All American (PAA) to Neutral
• MaxLinear (MXL) PT Raised to $105 at Stifel